Alzamend Total Current Assets vs Net Receivables Analysis

ALZN Stock

USD 0.73 0.01 1.35%

Alzamend Neuro financial indicator trend analysis is way more than just evaluating Alzamend Neuro prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alzamend Neuro is a good investment. Please check the relationship between Alzamend Neuro Total Current Assets and its Net Receivables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.

Total Current Assets vs Net Receivables

Total Current Assets vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alzamend Neuro Total Current Assets account and Net Receivables. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Alzamend Neuro's Total Current Assets and Net Receivables is -0.05. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Alzamend Neuro, assuming nothing else is changed. The correlation between historical values of Alzamend Neuro's Total Current Assets and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Alzamend Neuro are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Total Current Assets i.e., Alzamend Neuro's Total Current Assets and Net Receivables go up and down completely randomly.

Correlation Coefficient

-0.05

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Net Receivables

Most indicators from Alzamend Neuro's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alzamend Neuro current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.As of the 5th of May 2024, Issuance Of Capital Stock is likely to grow to about 6.1 M, while Selling General Administrative is likely to drop about 4.9 M.

Alzamend Neuro fundamental ratios Correlations

	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Deferred Long Term Liab	Total Current Assets	Common Stock	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital
Total Current Liabilities		0.31	-0.9	0.98	0.14	-0.26	-0.79	0.47	0.75	0.48	0.8	0.97	0.35	0.34	-0.46	0.49	0.49	0.83	0.79	-0.96	-0.63	0.83	0.96	0.35	0.83	0.35
Net Tangible Assets	0.31		-0.62	0.41	-0.08	0.0	-0.19	0.98	0.71	0.96	0.66	0.22	0.98	0.61	-0.96	0.96	0.96	0.68	0.28	-0.21	-0.82	0.65	0.23	0.98	0.68	0.98
Retained Earnings	-0.9	-0.62		-0.94	0.02	0.18	0.59	-0.75	-0.93	-0.73	-0.93	-0.86	-0.62	-0.65	0.72	-0.74	-0.74	-0.93	-0.69	0.88	0.8	-0.96	-0.83	-0.62	-0.93	-0.61
Accounts Payable	0.98	0.41	-0.94		0.0	-0.11	-0.76	0.56	0.83	0.54	0.82	0.95	0.42	0.42	-0.52	0.55	0.55	0.85	0.79	-0.94	-0.65	0.86	0.94	0.42	0.86	0.41
Other Assets	0.14	-0.08	0.02	0.0		-0.79	-0.12	-0.06	-0.26	0.12	-0.03	0.16	0.08	-0.37	-0.12	0.12	0.12	0.14	0.3	-0.05	-0.23	0.03	0.22	0.07	0.13	0.08
Net Receivables	-0.26	0.0	0.18	-0.11	-0.79		0.15	-0.05	0.04	-0.21	-0.29	-0.2	-0.19	-0.07	0.22	-0.22	-0.22	-0.24	-0.13	0.19	0.31	-0.24	-0.2	-0.19	-0.24	-0.19
Deferred Long Term Liab	-0.79	-0.19	0.59	-0.76	-0.12	0.15		-0.25	-0.41	-0.29	-0.6	-0.79	-0.23	0.02	0.27	-0.29	-0.29	-0.5	-0.56	0.73	0.41	-0.49	-0.82	-0.23	-0.51	-0.23
Total Current Assets	0.47	0.98	-0.75	0.56	-0.06	-0.05	-0.25		0.83	0.98	0.75	0.37	0.96	0.66	-0.97	0.98	0.98	0.81	0.43	-0.37	-0.88	0.78	0.37	0.96	0.81	0.96
Common Stock	0.75	0.71	-0.93	0.83	-0.26	0.04	-0.41	0.83		0.76	0.85	0.68	0.66	0.73	-0.74	0.77	0.77	0.92	0.64	-0.72	-0.76	0.94	0.65	0.67	0.92	0.66
Total Assets	0.48	0.96	-0.73	0.54	0.12	-0.21	-0.29	0.98	0.76		0.75	0.38	0.98	0.6	-1.0	1.0	1.0	0.8	0.44	-0.36	-0.9	0.76	0.39	0.98	0.8	0.98
Short Long Term Debt Total	0.8	0.66	-0.93	0.82	-0.03	-0.29	-0.6	0.75	0.85	0.75		0.75	0.67	0.64	-0.74	0.76	0.76	0.86	0.5	-0.78	-0.85	0.91	0.72	0.68	0.86	0.67
Other Current Liab	0.97	0.22	-0.86	0.95	0.16	-0.2	-0.79	0.37	0.68	0.38	0.75		0.24	0.24	-0.36	0.39	0.39	0.79	0.81	-0.98	-0.58	0.79	0.99	0.24	0.79	0.23
Total Stockholder Equity	0.35	0.98	-0.62	0.42	0.08	-0.19	-0.23	0.96	0.66	0.98	0.67	0.24		0.58	-0.99	0.98	0.98	0.68	0.29	-0.21	-0.84	0.64	0.25	1.0	0.68	1.0
Current Deferred Revenue	0.34	0.61	-0.65	0.42	-0.37	-0.07	0.02	0.66	0.73	0.6	0.64	0.24	0.58		-0.6	0.6	0.6	0.55	0.09	-0.38	-0.44	0.66	0.16	0.59	0.55	0.58
Net Debt	-0.46	-0.96	0.72	-0.52	-0.12	0.22	0.27	-0.97	-0.74	-1.0	-0.74	-0.36	-0.99	-0.6		-1.0	-1.0	-0.77	-0.4	0.34	0.9	-0.73	-0.37	-0.98	-0.77	-0.99
Cash	0.49	0.96	-0.74	0.55	0.12	-0.22	-0.29	0.98	0.77	1.0	0.76	0.39	0.98	0.6	-1.0		1.0	0.81	0.44	-0.37	-0.92	0.77	0.4	0.98	0.81	0.98
Cash And Short Term Investments	0.49	0.96	-0.74	0.55	0.12	-0.22	-0.29	0.98	0.77	1.0	0.76	0.39	0.98	0.6	-1.0	1.0		0.81	0.44	-0.37	-0.92	0.77	0.4	0.98	0.81	0.98
Common Stock Total Equity	0.83	0.68	-0.93	0.85	0.14	-0.24	-0.5	0.81	0.92	0.8	0.86	0.79	0.68	0.55	-0.77	0.81	0.81		0.82	-0.78	-0.86	0.98	0.78	0.68	1.0	0.67
Common Stock Shares Outstanding	0.79	0.28	-0.69	0.79	0.3	-0.13	-0.56	0.43	0.64	0.44	0.5	0.81	0.29	0.09	-0.4	0.44	0.44	0.82		-0.74	-0.55	0.73	0.84	0.27	0.82	0.28
Non Current Liabilities Total	-0.96	-0.21	0.88	-0.94	-0.05	0.19	0.73	-0.37	-0.72	-0.36	-0.78	-0.98	-0.21	-0.38	0.34	-0.37	-0.37	-0.78	-0.74		0.54	-0.81	-0.95	-0.21	-0.78	-0.2
Other Current Assets	-0.63	-0.82	0.8	-0.65	-0.23	0.31	0.41	-0.88	-0.76	-0.9	-0.85	-0.58	-0.84	-0.44	0.9	-0.92	-0.92	-0.86	-0.55	0.54		-0.83	-0.59	-0.84	-0.86	-0.84
Other Stockholder Equity	0.83	0.65	-0.96	0.86	0.03	-0.24	-0.49	0.78	0.94	0.76	0.91	0.79	0.64	0.66	-0.73	0.77	0.77	0.98	0.73	-0.81	-0.83		0.76	0.64	0.98	0.64
Total Liab	0.96	0.23	-0.83	0.94	0.22	-0.2	-0.82	0.37	0.65	0.39	0.72	0.99	0.25	0.16	-0.37	0.4	0.4	0.78	0.84	-0.95	-0.59	0.76		0.24	0.78	0.24
Net Invested Capital	0.35	0.98	-0.62	0.42	0.07	-0.19	-0.23	0.96	0.67	0.98	0.68	0.24	1.0	0.59	-0.98	0.98	0.98	0.68	0.27	-0.21	-0.84	0.64	0.24		0.68	1.0
Capital Stock	0.83	0.68	-0.93	0.86	0.13	-0.24	-0.51	0.81	0.92	0.8	0.86	0.79	0.68	0.55	-0.77	0.81	0.81	1.0	0.82	-0.78	-0.86	0.98	0.78	0.68		0.67
Net Working Capital	0.35	0.98	-0.61	0.41	0.08	-0.19	-0.23	0.96	0.66	0.98	0.67	0.23	1.0	0.58	-0.99	0.98	0.98	0.67	0.28	-0.2	-0.84	0.64	0.24	1.0	0.67

Click cells to compare fundamentals

Alzamend Neuro Account Relationship Matchups

Alzamend Neuro fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	992.3K	899.6K	1.2M	2.9M	3.3M	3.5M
Net Tangible Assets	821.6K	2.0M	13.4M	3.0M	3.5M	3.3M
Retained Earnings	(11.8M)	(16.8M)	(29.2M)	(44.1M)	(39.7M)	(37.7M)
Accounts Payable	929.6K	503.6K	1.2M	2.9M	3.3M	3.5M
Net Receivables	424.4K	285.4K	194.3K	16.2K	14.6K	13.9K
Total Current Assets	1.8M	2.9M	14.4M	5.8M	6.7M	4.5M
Common Stock	6.5K	6.7K	9.5K	9.7K	11.1K	7.4K
Total Assets	1.8M	2.9M	14.5M	5.9M	6.8M	5.9M
Other Current Liab	62.7K	60.7K	2.1K	2.9M	3.3M	3.5M
Total Stockholder Equity	821.7K	2.0M	13.4M	3.0M	3.5M	4.3M
Net Debt	(90.2K)	(1.6M)	(14.1M)	(5.1M)	(4.6M)	(4.9M)
Cash	90.3K	1.9M	14.1M	5.1M	5.9M	4.7M
Cash And Short Term Investments	90.3K	1.9M	14.1M	5.1M	5.9M	4.7M
Common Stock Total Equity	6.5K	6.7K	9.5K	9.7K	11.1K	8.5K
Liabilities And Stockholders Equity	1.8M	2.9M	14.5M	5.9M	6.8M	5.9M
Other Current Assets	1.5M	983.3K	349.7K	694.9K	625.4K	756.9K
Other Stockholder Equity	27.6M	33.7M	42.5M	47.1M	54.2M	38.2M
Total Liab	992.3K	899.6K	1.2M	2.9M	3.3M	3.5M
Net Invested Capital	821.6K	2.3M	13.4M	3.0M	3.5M	4.4M
Capital Stock	6.6K	6.8K	9.5K	9.7K	11.1K	8.6K
Net Working Capital	821.7K	2.0M	13.2M	3.0M	3.4M	4.3M

Pair Trading with Alzamend Neuro

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alzamend Neuro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alzamend Neuro will appreciate offsetting losses from the drop in the long position's value.

Moving together with Alzamend Stock

0.64	EGRX	Eagle Pharmaceuticals Earnings Call This Week	Pair Corr
0.78	BMY	Bristol Myers Squibb Earnings Call This Week	Pair Corr
0.75	JNJ	Johnson Johnson Financial Report 18th of July 2024	Pair Corr

Moving against Alzamend Stock

0.62	QLI	Qilian International	Pair Corr
0.56	CGC	Canopy Growth Corp Financial Report 27th of June 2024	Pair Corr
0.51	MRK	Merck Company Financial Report 6th of August 2024	Pair Corr
0.51	SNDL	SNDL Inc Earnings Call This Week	Pair Corr
0.48	IMCC	Im Cannabis Corp Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to Alzamend Neuro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alzamend Neuro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alzamend Neuro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alzamend Neuro to buy it.

The correlation of Alzamend Neuro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alzamend Neuro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alzamend Neuro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Alzamend Neuro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock:

How To Invest In Alzamend

Details

Is Alzamend Stock a good investment?

Details

What is Alzamend Neuro's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.

Note that the Alzamend Neuro information on this page should be used as a complementary analysis to other Alzamend Neuro's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Alzamend Stock analysis

When running Alzamend Neuro's price analysis, check to measure Alzamend Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alzamend Neuro is operating at the current time. Most of Alzamend Neuro's value examination focuses on studying past and present price action to predict the probability of Alzamend Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alzamend Neuro's price. Additionally, you may evaluate how the addition of Alzamend Neuro to your portfolios can decrease your overall portfolio volatility.

	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Bonds Directory Find actively traded corporate debentures issued by US companies

Is Alzamend Neuro's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.82)

Return On Assets

(1.67)

Return On Equity

(11.96)

The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alzamend Total Current Assets vs Net Receivables Analysis

Total Current Assets vs Net Receivables

Total Current Assets vs Net Receivables Correlation Analysis

Correlation Coefficient

Total Current Assets

Net Receivables

Alzamend Neuro fundamental ratios Correlations

Alzamend Neuro Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alzamend Neuro fundamental ratios Accounts

Pair Trading with Alzamend Neuro

Moving together with Alzamend Stock

Moving against Alzamend Stock

Complementary Tools for Alzamend Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Capital Stock	+ 1.0	Common Stock Total Equity

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Net Working Capital	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Invested Capital	- 0.98	Net Debt